Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs A Comprehensive Review of Phase 3 Efficacy and Safety
- Citation:
- Bird, P., W. Bensen, B. El-Zorkany, J. Kaine, B. H. Manapat-Reyes, V. k Pascual-Ramos, D. Witcombe, K. Soma, R. Zhang, and K. Thirunavukkarasu, "Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs A Comprehensive Review of Phase 3 Efficacy and Safety", JCR: Journal of Clinical Rheumatology, vol. 25-3, issue 03, pp. 115-126, 2019.